It has been widely demonstrated that rat amylin, with 3 amino acid differences from human amylin, does not have aggregating characteristics.13 Pramlintide, an amylin analog based on rat amylin sequence so that it cannot aggregate, is a US Food and Drug Administration–approved and effective drug for type 2 diabetes38 with a favorable safety profile in clinical use.39 Thus, pramlintide could be investigated as a repurposed drug for AD for patients who have a low plasma amylin concentration. Here, IAPP is linked to Alzheimer disease.